CY1123058T1 - Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων - Google Patents

Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων

Info

Publication number
CY1123058T1
CY1123058T1 CY20201100552T CY201100552T CY1123058T1 CY 1123058 T1 CY1123058 T1 CY 1123058T1 CY 20201100552 T CY20201100552 T CY 20201100552T CY 201100552 T CY201100552 T CY 201100552T CY 1123058 T1 CY1123058 T1 CY 1123058T1
Authority
CY
Cyprus
Prior art keywords
disorders
treatment
methods
autism spectrum
bicyclic compounds
Prior art date
Application number
CY20201100552T
Other languages
English (en)
Inventor
Lawrence Irwin Glass
Michael John Bickerdike
Michael Frederick Snape
Patricia Perez DE COGRAM
Original Assignee
Neuren Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Limited filed Critical Neuren Pharmaceuticals Limited
Publication of CY1123058T1 publication Critical patent/CY1123058T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Οι υλοποιήσεις αυτής της εφεύρεσης παρέχουν συνθέσεις και μεθόδους για τη θεραπευτική χρήση δικετοπιπεραζινών που περιλαμβάνουν κυκλική G-2-Αλλυλο Προλίνη και άλλες κυκλικές ενώσεις Γλυκυλο Προλίνης για τη θεραπεία συμπτωμάτων Διαταραχών του Φάσματος του Αυτισμού και Νευροαναπτυξιακών Διαταραχών όπως επίσης και για την παρασκευή φαρμάκων που περιλαμβάνουν δισκία, κάψουλες, υγρά σκευάσματα, γέλες, ενέσιμα διαλύματα, κι άλλα σκευάσματα που είναι χρήσιμα για τη θεραπεία τέτοιων καταστάσεων.
CY20201100552T 2013-07-25 2020-06-17 Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων CY1123058T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361958329P 2013-07-25 2013-07-25
PCT/US2014/047801 WO2015013397A2 (en) 2013-07-25 2014-07-23 Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders

Publications (1)

Publication Number Publication Date
CY1123058T1 true CY1123058T1 (el) 2021-10-29

Family

ID=52393968

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100552T CY1123058T1 (el) 2013-07-25 2020-06-17 Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων

Country Status (14)

Country Link
US (3) US9867823B2 (el)
EP (1) EP3024463B1 (el)
JP (1) JP6574769B2 (el)
CY (1) CY1123058T1 (el)
DK (1) DK3024463T3 (el)
ES (1) ES2797374T3 (el)
HR (1) HRP20201002T1 (el)
HU (1) HUE049302T2 (el)
LT (1) LT3024463T (el)
PL (1) PL3024463T3 (el)
PT (1) PT3024463T (el)
RS (1) RS60679B1 (el)
SI (1) SI3024463T1 (el)
WO (1) WO2015013397A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912843YA (en) * 2016-05-26 2020-02-27 Amino Up Chemical Co Ltd Sleep improving agent
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10467828B2 (en) * 2017-03-06 2019-11-05 J. J. Keller & Associates, Inc. Electronic logging device
AU2018323787A1 (en) * 2017-08-28 2020-04-09 Vitality Wellness (Nz) Limited Improvements in IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
MA50463A (fr) * 2017-10-27 2020-09-02 Amo Pharma Ltd Méthodes de traitement du syndrome de phelan mcdermid à l'aide de farnésyl-dibenzodiazépinones
JP6598412B1 (ja) * 2019-06-04 2019-10-30 ゼライス株式会社 認知機能改善用食品
IL292408A (en) * 2019-10-22 2022-06-01 Neuren Pharmaceuticals Ltd Bicyclic compounds and method of using them for the treatment of Pete Hopkins syndrome
CA3156680A1 (en) * 2019-10-28 2021-05-06 Acadia Pharmaceuticals Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） 一种广泛脑区神经元树突发育障碍动物模型的制备与应用
KR20240038994A (ko) 2021-07-20 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 염증성 장애를 치료하기 위한 부틸로필린-유사 2 제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511390A (en) 1983-06-10 1985-04-16 E. I. Du Pont De Nemours And Company Aralkylcarbamoyl peptide alcohols
DE3502041A1 (de) 1985-01-23 1986-07-24 Grünenthal GmbH, 5190 Stolberg Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
US5686423A (en) 1996-02-16 1997-11-11 Department Of Health, The Executive Yuan, Republic Of China Di-and tri-peptide mimetic compounds for Parkinson's disease
EP1200440A1 (en) 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
UA77515C2 (en) * 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
HUE028528T2 (en) 2003-09-03 2016-12-28 Neuren Pharmaceuticals Ltd Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
US8222293B2 (en) * 2004-05-24 2012-07-17 Regents of the University of Carolina Treating learning deficits with inhibitors of Hmg CoA reductase
US20070199096A1 (en) 2005-11-14 2007-08-23 E.I. Du Pont De Nemours And Company Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content
JP5220724B2 (ja) * 2006-03-14 2013-06-26 ニューレン ファーマシューティカルズ リミテッド グリシル−２−メチルプロリルグルタミン酸塩の経口製剤
WO2011109448A1 (en) * 2010-03-05 2011-09-09 Baylor Research Institute Involvement of androgen/androgen receptor pathway in fabry disease
WO2011146109A2 (en) 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate

Also Published As

Publication number Publication date
PL3024463T3 (pl) 2020-10-05
US11197856B2 (en) 2021-12-14
ES2797374T3 (es) 2020-12-02
US20170020869A1 (en) 2017-01-26
EP3024463A4 (en) 2017-03-01
EP3024463B1 (en) 2020-03-25
SI3024463T1 (sl) 2020-08-31
US20180140601A1 (en) 2018-05-24
HRP20201002T1 (hr) 2020-10-16
US20200163961A1 (en) 2020-05-28
WO2015013397A2 (en) 2015-01-29
JP2016525547A (ja) 2016-08-25
JP6574769B2 (ja) 2019-09-11
RS60679B1 (sr) 2020-09-30
US10548892B2 (en) 2020-02-04
PT3024463T (pt) 2020-06-30
EP3024463A2 (en) 2016-06-01
LT3024463T (lt) 2020-07-10
HUE049302T2 (hu) 2020-09-28
US9867823B2 (en) 2018-01-16
DK3024463T3 (da) 2020-06-29
WO2015013397A3 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CY1123058T1 (el) Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
EA201391106A1 (ru) Новые гетероциклические производные
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CL2014002732A1 (es) Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras.
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112015006029A2 (pt) compostos aza bicíclicos como agonistas de receptor m1 muscarínicos
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CY1119036T1 (el) Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa